Document is current
Any future updates will be listed below
-
Authors
Albinger, Nawid http://orcid.org/0000-0003-2989-4020
Pfeifer, Rita
Nitsche, Marcus
Mertlitz, Sarah
Campe, Julia
Stein, Katja
Kreyenberg, Hermann http://orcid.org/0000-0003-3575-9175
Schubert, Ralf
Quadflieg, Melissa
Schneider, Dina
Kühn, Michael W. M. http://orcid.org/0000-0002-6434-9303
Penack, Olaf http://orcid.org/0000-0003-4876-802X
Zhang, Congcong
Möker, Nina
Ullrich, Evelyn http://orcid.org/0000-0001-8530-1192
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (CRC1292, CRC1292)
Deutsche Krebshilfe (70114180)
- License Information
-
More Information
Article History
Received: 14 December 2021
Revised: 18 February 2022
Accepted: 22 February 2022
First Online: 13 April 2022
Competing interests
: RP, MN, MQ, CZ, and NM are employees of Miltenyi Biotec. DS is employee of Lentigen Technology, Inc., a Miltenyi Biotec Company. MWMK is a consultant for Pfizer and Abbvie and receives travel support from Celgene and Daiichi Sankyo. OP and EU have no COIs directly related to this manuscript. OP has received honoraria or travel support from Astellas, Gilead, Jazz, MSD, Neovii Biotech, Novartis, Pfizer, and Therakos. He has received research support from Gilead, Incyte, Jazz, Neovii Biotech, and Takeda and is member of advisory boards to Jazz, Gilead, MSD, Omeros, Priothera, Shionogi, and SOBI. EU has a sponsored research project with Gilead. Remaining authors declare no conflict of interest.
